December 12, 1978  
Release # 78-104

WASHINGTON, D.C. (Dec. 12) -- Armour Pharmaceutical Company and the U.S. Consumer Product Safety Commission (CPSC) today announced that Armour will replace the child-resistant caps on approximately 140,000 100-tablet bottles of prescription thyroid tablets. Efficacy and safety of the tablets themselves are not in question and no recall is involved.

The firm voluntarily initiated the cap replacement program, which involves only those packages held in its warehouses, after Commission testing indicated that some adults might be unable to properly reclose the safety feature of the present package during use in the home.

Regulations under the Poison Prevention Packaging Act currently require that at least 90% of those adults tested be able, not only to open the packages, but also to properly close them to protect young children from accidentally swallowing the contents.

In addition to replacing caps on current inventory, Armour plans to continue its on-going safety packaging program to meet its own standards of quality and to assure compliance with CPSC regulations.

In presenting this matter to the Commission, the staff acknowledged that upon receipt of the results of Commission testing, Armour promptly stopped distribution of the product in question and took immediate action to investigate and correct the problem.